Taken together, both the ex vivo omental system and in vivo tumor xenograft mouse model support our notion that targeting AMPK/ACC/FASN for lipogenesis and AMPK/TAK1/NF-κB oncogenic signaling is able to inhibit metastatic dissemination of ovarian cancer cells in the peritoneal cavity. The gene discussed is PRKAA1; the disease is ovarian cancer.